The major strength of our study is that this is the first international validation of the IGF-CTP score, and it is tested through an independent prospective validation cohort in patients with different demographics, geographical location, hepatitis status and other HCC risk factors from those of the original cohorts. This evidence concerns the gene IGF1 and hepatitis A virus infection.